Former Chief Executive Officer · ACADIA PHARMACEUTICALS INC (ACAD)

Stephen Davis

A named executive officer of ACADIA PHARMACEUTICALS in every fiscal year CompBrief holds from FY2016 to FY2024. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2024

$12,206,915

Salary $648,599Stock awards $4,911,872

FY2022: $14,028,139

1st of 6 named executive officers at Acadia Pharmaceuticals by FY2024 total.

6 named officers on file for ACADIA PHARMACEUTICALS, FY2024

Stephen Davis’s pay file — $29

  • 8 fiscal years of pay, line by line
  • 11 equity grants, each cited to its filing
  • ACAD’s disclosed peer group of 23 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how ACADIA PHARMACEUTICALS’s whole pay program stands against its peers

  • ACADIA PHARMACEUTICALS’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on ACAD→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 25, 2025 (DEF 14A).

Free

Get Stephen Davis’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Stephen Davis compensation by year

ACADIA PHARMACEUTICALS Summary Compensation Table · all 8 fiscal years held
In US dollars, as ACADIA PHARMACEUTICALS reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2024
Salary$675,992$700,000$719,833$743,705$767,624$792,831$822,316$648,599
Bonus$437,705$0$0$0$0$0$0$0
Stock awards$0$0$505,400$3,140,000$3,262,978$4,355,433$8,926,598$4,911,872
Option awards$8,133,720$13,905,418$4,771,631$3,127,738$3,273,559$4,403,433$3,643,271$3,516,219
Non-equity incentive$0$535,938$493,806$597,485$438,601$196,654$615,810$0
Pension and deferred compensation——$0$0$0$0$0$0
All other$14,030$16,790$17,362$22,318$20,425$44,937$20,144$3,130,226
Total$9,261,447$15,158,146$6,508,032$7,631,245$7,763,187$9,793,289$14,028,139$12,206,915

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: ACADIA PHARMACEUTICALS INC DEF 14A filed April 25, 2025, accession 0000950170-25-058827, and prior-year filings.

How this page was built: the ACADIA PHARMACEUTICALS INC filed document, accession 0000950170-25-058827. Every figure is read from that document and cited to the page and table it appears in. Filed April 25, 2025.

$9.3M
$15.2M
$6.5M
$7.6M
$7.8M
$9.8M
$14.0M
$12.2M
FY16
FY17
FY18
FY19
FY20
FY21
FY22
FY24
SalaryBonusNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2024 year-end
TypeUnvested unitsValue at year-endExercise price
PSU138,977$2,550,228—
RSU69,333$1,272,261—
RSU44,782$821,750—
RSU17,334$318,079—
Option161,130—$17.84
Option104,658—$21.75
Option19,828—$25.75

Per the Outstanding Equity Awards at Fiscal Year-End table in ACADIA PHARMACEUTICALS INC's FY2024 proxy; value at the fiscal year-end close, as the company printed it.

ACADIA PHARMACEUTICALS’s named executive officers, FY2024

as the company reported each
Named executive officerRoleFY2024 total
Stephen Davis · this pageFormer Chief Executive Officer$12,206,915
Catherine Owen AdamsChief Executive Officer$7,594,107
Elizabeth ThompsonExecutive Vice President, Head of Research and Development$4,261,944
Thomas GarnerExecutive Vice President, Chief Commercial Officer$3,670,951
Jennifer RhodesExecutive Vice President, Chief Legal Officer and Secretary$3,267,348
Mark SchneyerExecutive Vice President, Chief Financial Officer$2,517,513

Board service

ACADIA PHARMACEUTICALS board · FY2021–FY2022

How this board is paid

Company policy: ACADIA PHARMACEUTICALS pays directors a $50,000 cash retainer and $300,000 in Options and RSUs. As stated in ACADIA PHARMACEUTICALS's FY2022 proxy.

The full ACADIA PHARMACEUTICALS compensation record

free company brief

This page is one person within ACADIA PHARMACEUTICALS's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are ACADIA PHARMACEUTICALS's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Stephen Davis's compensation dossier · One-time report. No refunds.